| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 2,650 | 2,725 | 28.06. | |
| 2,655 | 2,720 | 27.06. |
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | ORYZON GENOMICS, S.A.: ORYZON announces the voting results from its Ordinary General Shareholders' Meeting | ||
| Mi | Oryzon Genomics, S.A.: ORYZON to Host Virtual KOL Event on July 9, 2025 | ||
| Di | Oryzon Genomics - A step closer to a new treatment paradigm in BPD | Oryzon Genomics has submitted the Phase III clinical trial protocol to the FDA for its lysine-specific demethylase 1 (LSD1) inhibitor, vafidemstat, in borderline personality disorder (BPD), marking... ► Artikel lesen | |
| Mo | Oryzon Genomics, S.A.: ORYZON Announces Submission of Phase III Protocol to FDA to Initiate PORTICO-2 Trial of Vafidemstat in Borderline Personality Disorder (BPD) Patients | PORTICO-2 designed to validate vafidemstat's efficacy in reducing aggression in BPD patientsPrimary endpoint: STAXI-2 Trait Anger (patient-reported)Key secondary endpoint: Overt Aggression Scale-Modified... ► Artikel lesen | |
| Mo | ORYZON GENOMICS, S.A.: ORYZON announces the submission to the FDA of the clinical trial protocol for its Phase III PORTICO-2 trial of vafidemstat in Borderline Personality Disorder patients |
